Product Images Toviaz
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Toviaz NDC 69189-0242 by Avera Mckennan Hospital, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Fesoterodine ER 4 mg tablet label - 6918902421
Fesoterodine fumarate ER is a medication represented by Toviaz 4mg tablet manufactured by Pfizer. The hospital lot number is APF15J05-M and the expiration date is 10/04/2016. NDC number for the product is 6918902421. This medication was available at Avera McKennan hospital located in Sioux Falls.*
Chemical Structure - toviaz 01
Figure 1 - toviaz 02
The text shows the mean change from baseline in the number of micturitions per 24 hours. It includes a figure depicting the change in the number of micturitions per 24 hours over weeks 2, 8, and 12. The study involved a placebo group (N=279) and a Toviaz treatment group (65). There is no further information available.*
Figure 2 - toviaz 03
The image shows the change in urge incontinence episodes per 24 hours over 12 weeks in Study 1, with data for the placebo group (N=211) and two doses of Toviaz (N=199 for 4mg and N=223 for 8mg). The y-axis displays the change from baseline in urge incontinence episodes per 24 hours and the x-axis displays the weeks.*
Figure 3 - toviaz 04
This is a report on a clinical study. The mean change from the baseline in the frequency of urination (number of micturitions per 24 hours) was -0.5. Figure 3 shows the change in the number of micturitions per 24 hours over a period of 12 weeks in Study 2, with data points at 2, 8, and 12 weeks. The study had three groups: a Placebo group with 266 participants, a Toviazdmg group with 267 participants, and a Tovazsmg group with 267 participants.*
Figure 4 - toviaz 05
This is a graph showing the change in urge incontinence episodes per 24 hours in Study 2 over the course of 12 weeks for three different groups: a placebo group (205 participants), a Toviaz 4mg group (228 participants), and a Toviaz 8mg group (218 participants). The y-axis measures the change in episodes while the x-axis measures the weeks of the study.*
Logo - toviaz 06
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.